Relevant? “While we still have a long research
Post# of 148294
(Total Views: 421)
Posted On: 02/25/2021 9:48:11 PM
Relevant?
“While we still have a long research path ahead of us, these findings suggest that if we can develop drugs to control this context-specific regulatory T-cell pathway in cancer patients, we can make them even more responsive to immunological checkpoint therapies.”
https://www.genengnews.com/news/blocking-a-tr...5551289H0I
“While we still have a long research path ahead of us, these findings suggest that if we can develop drugs to control this context-specific regulatory T-cell pathway in cancer patients, we can make them even more responsive to immunological checkpoint therapies.”
https://www.genengnews.com/news/blocking-a-tr...5551289H0I
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼